Anavex Life Sciences Corp. Stock News

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2026 Annual Meeting of Stock...

-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders – -- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders –

-- Proxy advisor recommends voting  “ FOR” two of PVG's director nominees and “AGAINST” two incumbent director nominees including the board's current chair on the GOLD Universal Proxy Card –

-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board's nominees –

ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS' Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or “the Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases wit...

CENTENNIAL, Colo., Sept. 10, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ: AVXL) ("Anavex" or the "Company"), today announced that it will host an investor conference call to discuss its campaign for change in the Anavex Board of Directors at the upcoming 2026 Annual Meeting of Stockholders.

CENTENNIAL, Colo., Sept. 09, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (Nasdaq: AVXL "Anavex" or the "Company"), believes the Anavex Board of Directors should be replaced and an experienced CEO should be hired.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie K...